Menu Close

The Arthritis Advocate, Volume 7

Medication access: Approved does not mean accessible

Cheryl Koehn, Founder and President, Arthritis Consumer Experts

What does it really mean to have “access” to an arthritis medication?

In Canada, once Health Canada authorizes a medication and issues it a Drug Identification Number – or DIN – the manufacturer is permitted to market it. A DIN confirms that Health Canada has evaluated the medication and authorized it for sale.

But regulatory approval is only the first step. A medication can be approved, available for sale and remain out of reach for many of the people who need it.

For people living with autoimmune or inflammatory forms of arthritis – such as rheumatoid arthritis, spondyloarthritis and lupus – advanced therapies can be life-changing. They can reduce inflammation and pain, prevent irreversible joint and organ damage, preserve mobility and help people remain employed, care for their families and participate in their communities.

These medicines can also come with significant price tags. While under patent, some advanced therapies cost approximately $30,000 to $40,000 a year – or $2,500 to $3,400 each month.

Are they worth it? You bet they are.

Speak with someone for whom one of these medications is effective and they will tell you what it can mean: getting out of bed, walking without overwhelming pain, returning to work or simply being able to make plans without disease controlling every decision.

But a medication cannot improve a person’s life if they cannot obtain it.

After regulatory approval, patients may still face lengthy health technology assessments, price negotiations and public or private drug-plan decisions. Even once a medication is listed, restrictive eligibility criteria, prior authorization requirements, step therapy and high out-of-pocket costs can create further barriers. “Approved” and “accessible” are not the same thing.

Pharmaceutical companies that discover, develop and manufacture innovative medications deserve the opportunity to recover their investments, earn a profit, reward their investors and fund the next generation of treatments. Patent protection is intended to support that innovation by giving the patent holder a period of market exclusivity.

But over the past decade, the goal line has shifted for some brand-name – or innovator – companies. Instead of relying only on the patent protecting the original discovery, they may employ business and legal strategies designed to extend market exclusivity.

You may have seen terms such as “patent thickets,” “evergreening” or “product hopping” in the business news and wondered what they mean.

A patent thicket is created when numerous overlapping patents are filed around one medication. Evergreening generally involves seeking additional patents for modifications such as a new formulation, dosage or delivery device. Product hopping occurs when patients are moved from an older medication nearing the end of its patent protection to a slightly modified, newly patented version.

Not every secondary patent or product improvement is inappropriate. Some changes provide genuine benefits to patients. The important question is whether a new patent represents meaningful therapeutic innovation – or primarily serves to delay competition.

Taken together, these practices are often described as patent manipulation. They can force generic and biosimilar manufacturers into prolonged, costly litigation before they can bring lower-priced alternatives to market. This may discourage competition, extend monopoly-level pricing and delay savings for patients, employers, private insurers and public drug plans.

That does not serve patients or our healthcare systems.

Generics and biosimilars are not lesser medicines. They are rigorously evaluated for their safety and efficacy by Health Canada, and their lower prices can allow public and private drug plans to treat more people and reinvest savings into new medicines and other essential health services. (To learn more, you can visit the Patients and patents campaign.)

Medication access, then, must mean more than permission to sell a product. It must mean that the right patient can receive the right medication at the right time, based on a decision made with their health care provider – not on their postal code, income or ability to navigate a complicated reimbursement system.

Patients deserve a balanced pharmaceutical system: one that rewards true innovation while preventing misuse of patent protections; one that welcomes fair competition when legitimate patent protection ends; and one that measures success not simply by how many medications reach the market, but by how many people can actually receive the treatment they need.

Because a medication sitting behind a regulatory, legal or financial barrier is not truly accessible – access on paper is not access in real life..

Advocacy